5 Key Takeaways
-
1
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, with prevalence expected to rise to 288 million by 2040.
-
2
Pegcetacoplan and avacincaptad pegol are the first FDA-approved treatments for geographic atrophy secondary to dry AMD.
-
3
Pegcetacoplan significantly slowed GA lesion growth by 21%, while avacincaptad pegol reduced GA growth by 27% in clinical trials.
-
4
Despite slowing GA progression, both treatments showed limited clinically significant improvements in visual function outcomes.
-
5
The location and size of GA lesions are critical factors influencing the functional benefits of treatments like pegcetacoplan.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.